At a glance
ClinicalIndex Comparison RecordN/ACompleted· 111 enrolled
Drug / intervention
Axitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
POST MARKETING SURVEILLANCE STUDY TO OBSERVE SAFETY AND EFFICACY OF INLYTA (REGISTERED)
In Brief
An observational study evaluating Axitinib for Advanced Renal Cell Carcinoma. Completed, enrolled 111 participants across 1 site.
Detailed Summary
The objective of this study is to monitor the usage of INLYTA® in real practice, including the adverse events associated with INLYTA®.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Renal Cell Carcinoma
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartJul 2018
Primary CompletionApr 2021
Study CompletionAug 2021
TodayJul 2026
First PostedJun 5, 2014
Enrollment StartJul 17, 2018
Primary CompletionApr 21, 2021
Study CompletionAug 6, 2021
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.1 years ago
Interventions
Axitinibdrug
based on Axitinib approval